How can we prevent disease relapse in Graves' orbitopathy after immunosuppressive treatment?

Expert Rev Endocrinol Metab. 2022 Jul;17(4):269-274. doi: 10.1080/17446651.2022.2100344. Epub 2022 Jul 13.

Authors

Irene Campi¹, Laura Fugazzola^{1

2}

Affiliations

¹ Division of Endocrine and Metabolic Diseases and Laboratory of Endocrine and Metabolic Research, Istituto Auxologico Italiano, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
² Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

PMID: 35832000
DOI: 10.1080/17446651.2022.2100344

No abstract available

Keywords: Disease relapses; Glucocorticoids; Graves’ orbitopathy; Radioiodine; Rehabilitative Surgery; monoclonal antibodies.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Glucocorticoids
Graves Ophthalmopathy* / drug therapy
Humans
Iodine Radioisotopes
Recurrence

Substances

Glucocorticoids
Iodine Radioisotopes